After yesterday’s closing bell, the San Francisco-based biopharmaceutical company reported an adjusted loss of 16 cents per share, narrower than the loss of 27 cents per share anticipated by analysts.
Advertisement
Over the last twelve months Exelixis Inc’s stock price has increased from 6.62 to 9.39, a change of 41.84%. Following the acquisition, the director now owns 548,273 shares of the company’s stock, valued at $2,724,916.81. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Investors also continue to take note on the stock, especially on reports Exelixis, Inc. (NASDAQ:EXEL) traded up 0.90% during midday trading on Friday, reaching $11.17.
The stock’s price switched up 7.92% 20-Days Simple Moving Average, added 19.21% from 50-Days Simple Moving Average and positively 65.63% from 200 Days Simple Moving Average.
Exelixis, Inc. (NASDAQ:EXEL) [Trend Analysis] considering as most desiring stocks in active trading lead, shares ascend following opening to traded at $10.98 with volume of 8.58 Million shares.
Back on 8/11/2015 the company’s estimated EPS value was $-0.21 and it reported $-0.22 earnings per share (EPS) for the quarter ended on 6/2015.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, August 3rd. (EXEL) is projected as $26.97 Million where Low Revenue estimate and High Revenue Estimates are $18.5 Million and $37.6 Million respectively by 5 analysts.
A number of Wall Street analysts stated their opinion on the stock. Other net income expense for the quarter came in at $11.9 million compared to $12.1 million for the comparable period previous year.
Exelixis closed down -0.12 points or -1.29% at $9.15 with 50,15,326 shares getting traded on Tusday. (NYSE:CF) is $29.50 while analysts mean recommendation is 2.70. According to the analysts, the company has the Low Price target of $5 whereas, the Mean Target is estimated by the brokers is $8.33.
Separately, TheStreet Ratings team rates the stock as a “sell” with a ratings score of D-. Finally, Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a research report on Tuesday, June 7th. Current revenue movements show that, the company has set average revenue estimates of 17.96M covering forecast of 5 analysts. The company presently has an average rating of “Buy” and an average target price of $9.63.
Advertisement
At the recent close, Exelixis, Inc. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
